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Patient Perceptions of
Drug Risks and Benefits
Michael S. Brown, Linda J. Wastila,
Carol I. Barash and Louis Lasagna*

Introduction
Much effort has gone into identifying how people understand and
cope with the risks and benefits of modem technologies. 1 These
efforts were motivated by concerns that the development and adoption
of "needed" technologies were hampered by undue fears over risks and
a lack of appreciation for potential benefits. Subsequently, other
investigators, concerned about the effectiveness of public participation
in decisions about controversial technologies, sought to identify factors
influencing risk and benefit perceptions with the goal of improving
participatory processes. The resulting studies focused on controversial
technological issues such as atomic power, 2 chemical hazards,3 and
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1 Otway and Thomas, Reflections on Risk Perceptionand Policy, 2 RISK ANAL
69 (1982); Slovic, Perceptions of Risk, 236 SCIENCE 280 (1987); SOCIAL
CONSTRUCTION OF RISK (B. Johnson and Covello eds. 1987).
2 Slovic, Fischhoff and Lichtenstein, Images of Disaster:Perceptionsof Risks
from Nuclear Power, in ENERGY RISK MANAGEMENT (Goodman and Rowe eds.
1979); Brody, Fleischman and Galavotti, The Importance of Counting Cows: Social
and Economic Effects of a High Level Nuclear Waste Repository in Texas,
Proceedings of the Nuclear Waste Issues Conference, Waste Management, Tucson,
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electric powerlines. 4 Relatively few reports, however, addressed
patients' views of medication risks and benefits. The few studies that
have been conducted attempted to locate pharmaceutical risks in the
context of a range of technological hazards 5 and to compare patient
and physician assessments of the severity of risk.6
Traditional views of the physician-patient relationship hold that
patients are passive participants in decisions about medical risks and
7
benefits, while physicians are active evaluators and decision makers.
Patients, by virtue of having sought medical care, are presumed to have
transferred responsibility for making risk/benefit determinations to their
physicians. More recently, however, legal doctrines of informed
consent have supported patients' rights to know about medical risks and
benefits, as well as their right to participate in medical decisions. Such
doctrines rest on the assumption that useful risk/benefit information can
be communicated to patients who are interested in and capable of using
this information to make valid decisions. Although informed consent is,
according to these newer constructs, required in most medical
situations, it is not uniformly applied; indeed, it is generally only applied
in situations involving invasive procedures and experimental therapies.
Routine medication decisions rarely involve informed consent.
AZ, 4 Mar 1987.
3
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(1984).
4 Morgan, Slovic, Nair et al., PowerlineFrequencyElectric and MagneticFields.
A Pilot Study of Risk Perceptions,5 RISK ANAL 139 (1985).
5 Slovic, Fischhoff, and Lichtenstein, Factsvs. Fears: UnderstandingPerceived
Risk in SOCIETAL RISK ASSESSMENT: HOW SAFE IS SAFE ENOUGH? (Schwing and
Albers, eds. 1980).
6 Tallarida, Smith, Johnson and Blodget, Non-physicians and PhysiciansAssess
Severity of Disease States and Adverse Drug Reactions: Applications to Drug
Benefit Risk Measurement, 1 PHARM. MED. 41 (1984).
7 T. PARSONS, THE SOCIAL SYSTEM (1951); E. FREIDSON, PROFESSION OF
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Rather, attention tends to focus on compliance with prescribed
regimens. In this context, researchers view patient perceptions and
preferences regarding drugs as independent factors affecting their
compliance with the prescribed regimen. 8 Some experts doubt
patients' abilities to view the risks and benefits of drugs in a rational
manner, contending that perceptions of drugs involve "irrational" fears
that unduly influence patient and physician behavior.
An alternative approach suggests that while researchers cannot
expect patients to perform a technical risk/benefit analysis, it is
important to elicit their perceptions of drug risks, benefits, and
uncertainties. 9 This approach asserts that researchers must emphasize
patients' value judgments in risk/benefit decisions. These values are
held to be critical in determining the acceptability of therapeutic risks.
MEDICmN
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Research on factors that affect patients' perceptions of medical risks,
in such situations as coronary artery surgery and lung cancer, indicates
that there is a correlation between therapeutic choices and patient
values. 10 This work suggests that deviations from "rational" decision
making, i.e., that which is based on decision analysis, 11 frequently
occur. A variety of factors, including the way information is presented,

individual preference for gains over losses, availability of alternatives,
and desire for certain outcomes, influence both lay and expert decision
12
making abilities.
Previous studies, however, have not evaluated the role of other
variables, such as perceived health status or experience with disease and
drugs. Furthermore, these studies have failed to apply the findings from
other research involving different technological issues, such as nuclear
power, to the topic of drug risks and benefits. Such nonmedical
research suggests the influence of factors such as the patient's perceived
control of the situation, how information is communicated, attitudes
towards regulation, and personal relationships between risk takers and
risk mediators. 13

Risk/benefit perceptions play an important role in public policy
decisions. Congressional perception of uncontrolled drug risks has
10 Pauker, Coronary Artery Surgery: The Use of Decision Analysis, 85 ANN.
INTERN. MED. 8 (1976); McNeil, Pauker, Sox and Tversky, On the Elicitation of
PreferencesforAlternative Therapies,306 N. ENGL J. MED. 1259 (1982).
11 Eraker and Politser, How Decisions are Reached: Physician and Patient,97
ANN. INTERN. MED. 262 (1982).

12 Fischhoff, Slovic and Lichtenstein, Lay Foibles and Expert Fables in
Judgments About Risk in 3 PROGRESS IN RESOURCE MANAGEMENT AND

ENVIRONMENTAL PLANNING (O'Riordan and Turner eds. 1981).
13 NELKIN AND BROWN, supra note 3. Weinstein, Seeking Reassuring or
Threatening Information About Environmental Cancer, 2 J. BEHAV. MED. 125

(1979); Buss and Craik, Contemporary Worldviews: Personal and Policy
Implications,13 J. APPL. So. P. 259 (1983).
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prompted more stringent federal drug approval requirements, including
14
the passage of the 1962 Food, Drug and Cosmetic Act Amendments.
In contrast, perceptions that some drugs offer overwhelming benefits
for patients with specific diseases have led, on occasion, to policy and
regulatory changes which result in abbreviated drug review processes.
The most current case involved zidovudine, popularly known as AZT,
which was approved for acquired immunodeficiency syndrome (AIDS)
in only 107 days.
The study reported here was conceived as a pilot effort to elicit
patient perceptions of drug risks and benefits and to identify factors that
might affect these perceptions. Using a population based in hospital
outpatient clinics, we asked patients to identify how they viewed
adverse somatic and psychological effects of drugs, as well as presumed
benefits, including amelioration of symptoms, elimination of disease,
and improvements in psychosocial well-being. The first part of this
paper reports our findings of patient perceptions of drug risks and
benefits. The second part presents our analysis of factors that previous
research suggest may be important in shaping patient perceptions.
Methods
The study was structured around a questionnaire designed to elicit
patients' perceptions of the risks and benefits associated with their
medications. The questionnaire also extracted information on patients'
current health status, experiences with prescription drugs, knowledge of
drug effects, perceived level of control, and regulatory and political
views.
We sought a population likely to have diverse experiences with
prescription medications. For this reason, we recruited participants from
the oncology, arthritis, lipid, diabetes, and hypertension outpatient
14 P.L. 87-781, 76 Stat. 780 (1962). But see, e.g., P.L. 98-417, 98 Stat. 1585 §
101 (1984).
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clinics at a large, urban medical center. Because of the small number of
patients attending the diabetes and hypertension clinics, additional
patients with these conditions were enrolled from the general medicine
clinic.
Within each clinic, physicians screened their patients for their
willingness to participate in our study. The physicians then briefly
discussed the project with prospective candidates. Candidates received
an information sheet explaining the project and were allowed to decline
participation before being interviewed by one of the study investigators.
The investigator then approached those who did not decline and, after
obtaining the patient's informed consent, conducted, or scheduled for a
later time, a twenty to thirty minute interview. Participating patients also
completed a brief demographic questionnaire.
Due to constraints imposed by the hospital's institutional review
board, physicians were under no obligation to tell us if they or a patient
did not want to participate. Thus, we could not identify the patient
nonparticipation rate and whether those who did participate were
representative of the clinic population as a whole.
Trained interviewers (M.B., C.B. and B. Richard), guided by a
standard set of questions, were encouraged to ask follow-up questions
that would allow patients to develop well-considered answers. Each
interview was tape-recorded and the patients' responses were
transcribed and coded by staff unfamiliar with the project.
A coding scale was developed for each question on the interview
schedule. To reduce potential interviewer bias, a staff research assistant,
unconnected with the project, coded the interviews. The staff then
developed a database from the interview responses, imputing missing
data values when such information was reliably known.
We analyzed overall frequency responses, as well as responses
stratified by clinic, for both patients' perceptions of drug risks and
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benefits and the factors possibly related to these perceptions. To
determine if inter-clinic differences were significant, we calculated the
Chi-square statistic for nonparametric data (Kruskal-Wallis test). A nonparametric test was employed because of the ordinal nature of responses
and the small sample sizes when stratified by clinic. The p-values
associated with statistically significant findings (p < 0.10) are denoted in
parentheses.
In addition to the above analyses, we examined the relationship
between patients' perceptions of drug risks and benefits and the five
factors described above: current health status, experience with
medications, knowledge of drug effects, perceived sense of control, and
regulatory/political beliefs. To do this, we tested the association of
questions describing the five factors with the perception factors using
nonparametric correlation tests (Spearman Rank). Significant
correlations and associated p-values are specified in parentheses (p <

0.10).
Results
Group Characteristics
Of the 124 interviews conducted, 22 contained greater than 20%
missing or unintelligible responses, leaving 102 transcripts suitable for
analysis. Of the 102 interviewed patients, 26 came from the
hypertension clinic, 24 from the arthritis clinic, 23 from the oncology
clinic, 16 from the diabetes clinic, and 13 from the lipid clinic. The
majority of study participants were Caucasian (85%) and female (60%).
The average age was 55 years, with a range of 21 to 87. The average
annual household income was $25,000. Although 60% had acquired a
high school education, on the whole, the study population was less
15
educated than the average Massachusetts resident.
15 U.S. BUREAU OF THE CENSUs, STATISTICAL ABSTRACr OF THE UNITED STATES
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Perceptionsof Risks andBenefits
We first asked a series of questions designed to elicit a general
picture of patients' perceptions of drug risks and benefits. These
questions focused on patients' expectations of drug therapy, concerns
about anticipated drug side effects, projections of side effects severe
enough to warrant drug discontinuation, and beliefs about whether drug
discontinuation would result in clinical deterioration.
Table 1
Patients' perceptions of drug risks and benefits by clinic
CLINIC
Overall Oncology Arthritis Diabetes Lipid Hypertension
(n=102) (n=23)

(n=24)

(n=16)

(n=13)

(n=26)

PERCEPTION
Prescribed drug will
improve conditionl
Discontinuation
will cause clinical
deterioration 2
Concern about
side effects 3
Can imagine level
of side effects that
would result in
discontinuation4
-X2
_ 14.34,p=0. 006

50%

46%

78%

29%

16%

58%

84%

80%

90%

76%

76%

89%

53%

64%

56%

69%

41%

34%

72%

55%

88%

56%

91%

69%

2

X2 - 7 .23 ,p=0.12

3

X2 = 9 .3 8,p=0.05

4

X2 _8.88,p O0.06

Overall, the patients in the study had a positive view of their
medications and tended to focus on the benefits rather than the adverse
(106th Ed. 1986).
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aspects of their therapies. One half of all respondents expected their
prescribed medications to ameliorate their condition and to improve their
physical and mental well-being. Consistent with this belief, 84%
expected that discontinuing their drug treatments would result in clinical
deterioration.
A significant proportion of the study population were concerned
about the risks of their medications. Fifty-three percent of respondents
expressed varying degrees of concern about potential side effects,
whereas 47% were unconcerned about the side effects they were told
they might experience.
In contrast to views on the medicines they actually use, when asked
to envision a hypothetical situation, patients gave greater consideration
to drug risks. When asked if they could imagine a level of side effects
that would compel them to refuse medication, 72% said they could.
Only 24% said they would ignore the risks, asserting that they would
never refuse physician ordered medication.
There were inter-clinic differences in response to the question about
concern about potential side effects (p = 0.05). Diabetic patients
expressed the greatest concern (69%), with much of this anxiety related
to self administration using needles and syringes. Oncology patients
(64%) were also very concerned about side effects. In contrast, nearly
two-thirds of the patients in the hypertension clinic did not express any
concern about side effects.
A large proportion of arthritis patients (78%) believed that their
prescribed medication would greatly benefit their health, whereas lipid
(16%) and diabetic patients (29%) felt their medications were not as
likely to provide physical improvement (p = 0.006). Lipid patients
(91%), arthritis patients (88%), and oncology patients (55%) were more
likely to state they would refuse medication because of potential side
effects than were patients from the other clinics (p = 0.06).
FactorsAffecting Perceptions
We asked patients questions about five factors that might be
associated with their perceptions of drug risks and benefits. These
I RISK - Issues in Health &Safety 203 [Summer 1990]

factors included probing patients' 1)current health status; 2) experiences
with prescription drugs; 3) communication of medical and drug
information; 4) perceived level of control over their situations; and 5)
views on regulation and politics.
CurrentHealth Status: Overall, participants had mixed assessments
of their health status. Thirty percent were generally optimistic about their
diagnosed condition, 50% expressed some degree of worry, concern,
depression, or anger about their medical condition, and 20% expressed
indifference. Lipid patients tended to be the most comfortable with their
condition, whereas diabetic patients expressed the greatest pessimism.
No association was found between attitude towards current health status
and any of the factors describing perceptions of drug risks and benefits.
Experience with Medications: Nearly all patients (93%) were
currently taking prescription medication. Of those, 87% reported a high
degree of compliance in medication use. Self-reported compliance was
particularly high among oncology patients, who received chemotherapy
in a hospital setting, and hypertension patients (p = 0.02). Diabetic and
lipid patients reported the least degree of compliance following their
diagnosis. Past experience with medication use was also extensive;
more than 81% had taken some type of prescription drug in the past two
years, and 76% also indicated past or current usage of over-the-counter
medications.
Nearly one half (47%) of all surveyed patients said they had
experienced anticipated side effects. Additionally, 78% said that they
had experienced unexpected side effects. Patients from the oncology,
arthritis, and lipid clinics experienced anticipated side effects more
frequently than did patients from the other clinics. Hypertension patients
reported much fewer experiences with side effects.
Correlation analysis revealed a modest positive association between
concern about side effects and experience with expected side effects (R
= 0.31; p = 0.004). In contrast, there was an inverse association
between concern about adverse reactions and experience with
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unexpected side effects (R = -0.30; p = 0.00)
Communication of Information: Nearly two-thirds (64%) of the
respondents felt that their physician kept them well-informed about their
medical condition. In particular, lipid patients (91%) and oncology
patients (83%) believed they were well-informed. This finding may be
due to the fact that patients from these two clinics often were recruited
for organized clinical trials which require informed consent for patient
participation. In contrast, diabetic patients (32%) and hypertension
patients (38%) felt particularly ignorant about their illnesses.
Most patients (77%) received some type of drug-related information
from their physicians, including instructions for use or discontinuation
of the drug, benefits of the drug, and possible side effects associated
with drug therapy. The remaining 23% reported receiving no drugrelated information from their physician.
Although 80% of the respondents expressed satisfaction with and
understanding of the information initially given them regarding their
prescribed medication, 40% indicated a wish for more information after
beginning their medication regimens. In addition, patients (66%)
identified other sources of drug information, often relying on other
people, including nurses, pharmacists, family, and friends (66%).
Patients also referred to getting information from medical texts and
journals (49%). In particular, arthritis patients were especially inclined
to rely on research of the medical literature for information on their
condition and medications (74%; p = 0.006).
Overall, information-seeking behavior by patients was weakly
correlated with the degree of concern about side effects. There was a
slight positive association between concerned patients and discussion of
their medical condition and medications with pharmacists, nurses, and
people other than their physician (R = 0.21; p = 0.06). The use of
medical texts and journals as additional sources of drug information was
also positively associated with concern about drug side effects (R =
0.21; p = 0.07). In addition, a relationship was also found between the
I RISK -Issues in Health &Safety 203 [Summer 1990]

use of medical texts and potential discontinuation of prescribed drugs
due to severe side effects (R = 0.20; p = 0.08).

Patients' Sense of Control: When asked what was important in
deciding to take the prescribed medication, patients gave as reasons that
their condition would deteriorate if left untreated (47%), that their
physician insisted upon the recommended therapy (38%) or that they felt
they had no choice (15%). Hypertension patients (46%), as well as
those from the lipid clinic (75%), tended to base their decision largely
on their physicians' opinions, expressing a willingness to defer to
professional expertise and judgment. Fifty-two percent of oncology
patients took their medication because they believed that it would be
effective. No one directly referred to a drug's side effect profile as a
factor in making their decision to take or refuse the prescribed
medication.
Responses indicated a mixed view regarding the level of patient
autonomy in decision making. The majority (80%) believed that no
treatment alternatives existed to the taking the prescribed drug. This was
particularly true of the lipid patients (90%) and oncology patients (90%)
(p = 0.06). Only 37% of all respondents discussed their decision to take
or not take a prescribed drug with people other than their physician.
Correlation analysis revealed a modest positive association between
a patient's belief in the existence of alternatives besides the prescribed
medication and the future refusal of medication due to the degree of side
effects associated with the prescribed drug (R = 0.19; p = 0.09).
Political and Regulatory Views: Fewer patients responded to
questions about their attitudes towards drug regulations and the
availability of drugs in society than to questions about other factors
associated with perceptions about drug risks and benefits. This may be
due to the fact that many of the patients had never before considered the
questions posed in this section of the questionnaire.
Less than half (41%) of those who responded (n = 93) believed that
strict government regulation was necessary to protect the public's
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health, safety, and welfare. Forty-nine percent were ambivalent in their
assessment of the role of government regulation. Only 10% considered
current government regulation excessive.
In regard to drug regulation in particular, 36% trusted that the
current system worked well. The remaining respondents, however,
were either unaware that a drug regulatory system existed (31%) or, if
they were aware of such a system's existence, they mistrusted it (33%).
About half of the respondents (51%) believed that both the FDA and
the drug industry were adequately concerned about drug safety. Nearly
one third (32%) felt that the flow of new drugs on the market was
adequate; however, 26% believed that too few products were available
and another 26% believed that too many products were marketed.
Forty-eight percent of the oncology patients felt that the supply of
available drugs was scant (p = 0.001), whereas 40% of the patients
from the hypertension clinic considered the number of medications
available excessive (p = 0.001).
Of those patients who were not concerned about side effects, a large
percentage (48%) believed that stringent government regulations were
necessary to protect public safety and welfare. Only 26% of the patients
who were concerned about side effects indicated that strong government
regulation was necessary. One third of those patients who indicated that
they would refuse medication if the level of side effects was significant
considered the pharmaceutical industry and the FDA to be inadequately
concerned about drug safety.
When correlated with the perception factors, only one of the
regulatory variables showed an association; concern about side effects
was inversely associated with the belief that government regulation was
necessary (R = -0.23; p = 0.04)
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Discussion and Conclusions
Our results should be interpreted cautiously, as we had a limited
sample and used an open-ended interview structure. Because previous
studies have not focused on patients' understanding of risk/benefit
issues and decision making processes regarding medications, we were
exploring new paths to elicit patient perceptions of drug risks and
benefits. We realize that the many statistical relations examined may well
have generated spurious probability levels. Because many of the
participants had not previously considered the issues raised in the
interviews, future studies should evaluate alternative methods of
eliciting patient opinions and attitudes towards medication decisions.
Researchers may want to corroborate self-reported medication use and
health status with physician records to gain an additional perspective.
Further studies might be conducted that evaluate cultural and ethnic
influences on drug risk/benefit perceptions, as well as other
determinants of patient decision making practices. As future research
further identifies other variables which influence patients' perceptions of
drug risks and, ultimately, their medication-taking behaviors, it will be
possible to construct a definitive model which can serve as the basis for
more sophisticated studies.
To the extent that patients' perceptions and attitudes identified in this
study are representative of the general population, several conclusions
are suggested. First, public policy makers should continue to recognize
risk/benefit differentials based on the severity and chronicity of the
diagnosis. Indeed, the FDA is willing to tolerate more risk with
oncologic and AIDS drugs than, for example, with antihypertensive
medications. Second, it is possible that public concern about drug risks
is dependent upon the degree of government oversight of the drug
industry. A high level of regulation may be associated with an increased
public acceptance of drug risks. Conversely, decreased government
regulation of the pharmaceutical industry might result in an increase in
public concern about the safety of their medications.

